GPC Biotech Merger With Agennix May Have A Billionaire’s Reasons For Success
This article was originally published in The Pink Sheet Daily
Executive Summary
Key to the deal is investment by German billionaire Dietmar Hopps; GPC, troubled since satraplatin failed to meet trial endpoints, gains Agennix’s NCSLC candidate, talactoferrin.